ES2734076T3 - Preparación farmacéutica de anticuerpo anti-CD40 muy concentrada - Google Patents

Preparación farmacéutica de anticuerpo anti-CD40 muy concentrada Download PDF

Info

Publication number
ES2734076T3
ES2734076T3 ES12747045T ES12747045T ES2734076T3 ES 2734076 T3 ES2734076 T3 ES 2734076T3 ES 12747045 T ES12747045 T ES 12747045T ES 12747045 T ES12747045 T ES 12747045T ES 2734076 T3 ES2734076 T3 ES 2734076T3
Authority
ES
Spain
Prior art keywords
antibody
preparation
ser
concentration
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12747045T
Other languages
English (en)
Spanish (es)
Inventor
Ryosuke Endo
Tomoyoshi Ishikawa
Hiroyuki SUETOMO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Application granted granted Critical
Publication of ES2734076T3 publication Critical patent/ES2734076T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
ES12747045T 2011-02-17 2012-02-16 Preparación farmacéutica de anticuerpo anti-CD40 muy concentrada Active ES2734076T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011031894 2011-02-17
PCT/JP2012/053687 WO2012111762A1 (ja) 2011-02-17 2012-02-16 抗ｃｄ４０抗体の高濃度製剤

Publications (1)

Publication Number Publication Date
ES2734076T3 true ES2734076T3 (es) 2019-12-04

Family

ID=46672674

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12747045T Active ES2734076T3 (es) 2011-02-17 2012-02-16 Preparación farmacéutica de anticuerpo anti-CD40 muy concentrada

Country Status (5)

Country Link
US (1) US9125893B2 (ja)
EP (1) EP2676677B1 (ja)
JP (1) JP5458188B2 (ja)
ES (1) ES2734076T3 (ja)
WO (1) WO2012111762A1 (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1707627T3 (pl) * 2003-12-25 2013-04-30 Kyowa Hakko Kirin Co Ltd Mutant antagonistycznego przeciwciała anty-CD40
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
US9987356B2 (en) 2011-03-11 2018-06-05 Beth Israel Deaconess Medical Center, Inc. Anti-CD40 antibodies and methods of administering thereof
AU2014354384B2 (en) * 2013-11-29 2018-11-08 Ares Trading S.A. A liquid formulation of a fusion protein comprising TNFR and Fc region
CA2969847A1 (en) 2014-12-10 2016-06-16 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
EP3307322B1 (en) 2015-09-04 2021-02-17 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
CN109475603B (zh) 2016-06-20 2023-06-13 科马布有限公司 抗pd-l1抗体
US11471515B2 (en) 2016-11-09 2022-10-18 The Brigham And Women's Hospital, Inc. Restoration of tumor suppression using MRNA-based delivery system
CN112533613A (zh) 2018-02-06 2021-03-19 通用医疗公司 作为肿瘤免疫应答的生物标志物的重复rna
MA52889A (fr) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V Inc Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
WO2022006179A1 (en) 2020-06-29 2022-01-06 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
CN116963774A (zh) 2021-01-28 2023-10-27 瑞泽恩制药公司 用于治疗细胞因子释放综合征的组合物和方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
WO2005044854A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Antagonist anti-cd40 monoclonal antibodies and methods for their use
PL1707627T3 (pl) * 2003-12-25 2013-04-30 Kyowa Hakko Kirin Co Ltd Mutant antagonistycznego przeciwciała anty-CD40
ES2553987T3 (es) * 2003-12-25 2015-12-15 Kyowa Hakko Kirin Co., Ltd. Preparación farmacéutica de base acuosa estable que contiene anticuerpo
BRPI0608855A2 (pt) * 2005-03-08 2010-02-02 Pharmacia & Upjohn Co Llc composições de anticorpo anti - madcam processo para a preparação das mesmas e uso de anticorpo anti - madcam
CN101426817B (zh) 2006-04-21 2013-07-10 诺华有限公司 拮抗性抗-cd40抗体药物组合物
AU2007307107B2 (en) 2006-10-06 2011-11-03 Amgen Inc. Stable antibody formulations
CA2760185A1 (en) * 2009-05-04 2010-11-11 Abbott Biotechnology Ltd. Stable high protein concentration formulations of human anti-tnf-alpha antibodies
JP4432094B1 (ja) 2009-07-30 2010-03-17 ダイソートレーディング株式会社 パネルロック装置
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40

Also Published As

Publication number Publication date
US20130323267A1 (en) 2013-12-05
US9125893B2 (en) 2015-09-08
JP5458188B2 (ja) 2014-04-02
EP2676677A9 (en) 2014-05-07
JPWO2012111762A1 (ja) 2014-07-07
WO2012111762A1 (ja) 2012-08-23
EP2676677A4 (en) 2015-02-11
EP2676677B1 (en) 2019-05-22
EP2676677A1 (en) 2013-12-25

Similar Documents

Publication Publication Date Title
ES2734076T3 (es) Preparación farmacéutica de anticuerpo anti-CD40 muy concentrada
ES2902325T3 (es) Composición farmacéutica oftálmica
CN110062620B (zh) 液体药物组合物
CN106999581A (zh) 含有高浓度抗vegf抗体的稳定蛋白质溶液剂型
JP6027708B2 (ja) 安定な液体製剤
US20150359864A1 (en) Pharmaceutical composition containing peptides
AU2020290014B2 (en) Pharmaceutical parenteral composition of dual GLP1/2 agonist
KR20190071760A (ko) 약학적 제형 및 그의 제조 방법
CN103619347A (zh) Fgf-18冷冻干燥制剂
US20170239329A1 (en) Therapeutic composition comprising annexin v
RU2740185C2 (ru) Пептидная композиция
KR20160036530A (ko) 가용성 Fc 수용체의 고농축 제형
ES2833099T3 (es) Preparación de disolución estabilizada de una proteína de fusión de un anticuerpo de GLP-1R farmacéutica
ES2843685T3 (es) Composición farmacéutica líquida de eritropoyetina conjugada
JPWO2017164349A1 (ja) ＰＥＧ化抗ヒトＮＧＦ抗体Ｆａｂ’フラグメント含有医薬組成物
WO2017015198A1 (en) Stable aqeous formulations of natalizumab
CA3214867A1 (en) Performance-enhancing excipients and methods of reducing viscosity and increasing stability of biologic formulations
RU2783864C2 (ru) Фармацевтические композиции с il-2